- Details
- Ashish Kamat is joined by Laura Bukavina to discuss her work on the Microbiome of Bladder Cancer. Currently, we have little knowledge about the microbiome and bladder cancer. The research being done at Fox Chase and Case Western is comparing the beta diversity of bladder cancer patients compared to healthy controls to help think of ways to modulate the microbiome to improve the treatment of patien...
|
- Details
- Scott Tagawa joins Sam Chang to highlight the key topics of his discussion at the American Society for Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022. Dr. Tagawa provided a clinical perspective on antibody-drug conjugates in the treatment of urothelial carcinoma. Biographies: Scott T. Tagawa, MD, Associate Professor of Clinical Medicine, Clinical Urology, Medical Director, Genitourin...
|
- Details
- Alicia Morgans is joined by Frank Schumacher to discuss the study results assessing the association of functional outcomes by decision-making approaches in men with metastatic prostate cancer. Dr. Schumacher and colleagues assessed the association of shared decision-making vs. physician- or patient-directed decisions and measurement of patient quality of life, including patient-reported functional...
|
- Details
- Sophia Kamran joins Sam Chang to discuss her presentation from the GU ASCO 2022 Annual Meeting focusing on novel therapies in bladder cancer and their toxicities, discussing the role of bladder-sparing trimodality therapy with a focus on toxicity and functional outcomes. Biographies: Sophia C. Kamran, MD, Assistant Professor of Radiation Oncology, Harvard Medical School, Massachusetts General Hosp...
|
- Details
- David Schuster joins Phillip Koo in discussing the results of SPOTLIGHT, a phase 3, prospective, multicenter study assessing the detection rate of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence. The single-arm SPOTLIGHT imaging study, conducted in the United States and Europe evaluates the safety and diagnostic performance of 18F-rhPSMA-7.3 PET imaging in men with suspect...
|
- Details
- Joining Alicia Morgans is Mark Markowski to discuss the results of a phase Ib/II study of the oral agent sabizabulin, also known as VERU-111. There is an unmet need for additional therapies for men with metastatic castration-resistant prostate cancer (mCRPC). Dr. Markowski shares findings from this study presented at GU ASCO 2022 including recommended phase two dose, what they found in terms of th...
|
- Details
- Alicia Morgans is joined by Simon Crabb to discuss the analysis he presented at 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium regarding the rucaparib arm in the ATLANTIS trial among patients with metastatic urothelial carcinoma (mUC). ATLANTIS is a randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following c...
|
- Details
- Carissa Chu joins Sam Chang to discuss data on genetic changes and alterations in urothelial carcinoma. The purpose of the study is to characterize human epidermal growth factor receptor 2 (HER2) (ERBB2) and fibroblast growth factor receptor 3 (FGFR3) mutations in a prospectively collected cohort of urothelial cancers. Dr. Chu highlights the key findings from this study. Biographies: Carissa Chu,...
|
- Details
- Joining Alicia Morgans is Neal Shore to further highlight his team's presentation at this year's GU ASCO 2022 Annual Meeting focusing on evaluating the feasibility of instituting a hereditary cancer risk assessment (HCRA) protocol in their urological practice for prostate cancer patients. The results found were encouraging for the incorporation of recommended genomic screenings in community urolog...
|
- Details
- Joining Alicia Morgans is Scott Tagawa to review this year's GU ASCO 2022 highlights in prostate cancer and urothelial cancer. Dr. Tagawa highlights multiple presentations including the phase 1/2 study of ARV-110, The Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES), the VISION Phase 3 Trial, TROPHY-U-01 Cohort...
|
